AR126417A1 - Composición farmacéutica de virus no encapsulado - Google Patents
Composición farmacéutica de virus no encapsuladoInfo
- Publication number
- AR126417A1 AR126417A1 ARP220101800A ARP220101800A AR126417A1 AR 126417 A1 AR126417 A1 AR 126417A1 AR P220101800 A ARP220101800 A AR P220101800A AR P220101800 A ARP220101800 A AR P220101800A AR 126417 A1 AR126417 A1 AR 126417A1
- Authority
- AR
- Argentina
- Prior art keywords
- encapsulated virus
- recombinant non
- pharmaceutical composition
- virus vector
- encapsulated
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000006172 buffering agent Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 2
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000008215 water for injection Substances 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con el campo de la farmacéutica, terapia genética y medicina, específicamente con las composiciones farmacéuticas de un vector de un virus no encapsulado recombinante, en particular, el virus adeno-asociado recombinante (rAAV), cuyas composiciones pueden ser composiciones acuosas o liofilizadas y pueden utilizarse para el tratamiento y la prevención de varias enfermedades. Reivindicación 1: Una composición farmacéutica de un vector de virus no encapsulado recombinante que comprende los siguientes elementos: (i) Un vector de virus no encapsulado recombinante, (ii) Un agente amortiguador, (iii) Hidroxipropil b ciclodextrina, (iv) Un surfactante, (v) Cloruro de sodio, (vi) Cloruro de magnesio, (vii) Agua para inyección. Reivindicación 85: Una composición farmacéutica liofilizada de un vector de virus no encapsulado recombinante; esta composición luego de la reconstitución en un disolvente acuoso comprende los siguientes elementos: (i) Un vector de virus no encapsulado recombinante, (ii) Un agente amortiguador, (iii) Hidroxipropil b ciclodextrina, (iv) Un surfactante, (v) Cloruro de sodio, (vi) Cloruro de magnesio, (vii) Agua para inyección.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021120143A RU2021120143A (ru) | 2021-07-08 | Фармацевтическая композиция безоболочечного вируса |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126417A1 true AR126417A1 (es) | 2023-10-11 |
Family
ID=84800844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101800A AR126417A1 (es) | 2021-07-08 | 2022-07-08 | Composición farmacéutica de virus no encapsulado |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4367252A4 (es) |
| CN (1) | CN117999353A (es) |
| AR (1) | AR126417A1 (es) |
| CL (1) | CL2024000062A1 (es) |
| CO (1) | CO2024000073A2 (es) |
| CR (1) | CR20240004A (es) |
| EC (1) | ECSP24001599A (es) |
| MA (1) | MA63861A1 (es) |
| MX (1) | MX2024000472A (es) |
| WO (1) | WO2023282796A2 (es) |
| ZA (1) | ZA202400124B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120569217A (zh) * | 2023-01-19 | 2025-08-29 | 优尼科生物制药有限公司 | 基因递送媒介物的药物配制品 |
| WO2025051970A2 (en) * | 2023-09-06 | 2025-03-13 | Dinaqor Ag | Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations |
| WO2025114524A1 (en) * | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120219590A1 (en) * | 2011-02-24 | 2012-08-30 | Paxvax, Inc. | Formulations useful for spray drying vaccines |
| US20130216499A1 (en) * | 2012-02-17 | 2013-08-22 | Wenlin Huang | Compositions of recombinant human endostatin adenovirus injections and methods of production |
| MX369156B (es) * | 2013-09-19 | 2019-10-30 | Janssen Vaccines & Prevention Bv | Formulaciones de adenovirus mejoradas. |
| JP7545210B2 (ja) * | 2016-11-04 | 2024-09-04 | 武田薬品工業株式会社 | アデノ随伴ウイルス製剤 |
| WO2020023612A1 (en) * | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
-
2022
- 2022-07-04 WO PCT/RU2022/050212 patent/WO2023282796A2/en not_active Ceased
- 2022-07-04 MX MX2024000472A patent/MX2024000472A/es unknown
- 2022-07-04 CR CR20240004A patent/CR20240004A/es unknown
- 2022-07-04 EP EP22838112.5A patent/EP4367252A4/en active Pending
- 2022-07-04 CN CN202280061040.XA patent/CN117999353A/zh active Pending
- 2022-07-04 MA MA63861A patent/MA63861A1/fr unknown
- 2022-07-08 AR ARP220101800A patent/AR126417A1/es unknown
-
2024
- 2024-01-02 ZA ZA2024/00124A patent/ZA202400124B/en unknown
- 2024-01-05 CO CONC2024/0000073A patent/CO2024000073A2/es unknown
- 2024-01-08 CL CL2024000062A patent/CL2024000062A1/es unknown
- 2024-01-08 EC ECSENADI20241599A patent/ECSP24001599A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4367252A2 (en) | 2024-05-15 |
| EP4367252A4 (en) | 2025-04-30 |
| WO2023282796A3 (en) | 2023-02-16 |
| ZA202400124B (en) | 2024-11-27 |
| WO2023282796A2 (en) | 2023-01-12 |
| MX2024000472A (es) | 2024-02-12 |
| ECSP24001599A (es) | 2024-02-29 |
| CN117999353A (zh) | 2024-05-07 |
| CL2024000062A1 (es) | 2024-06-14 |
| CR20240004A (es) | 2024-06-11 |
| MA63861A1 (fr) | 2024-10-31 |
| CO2024000073A2 (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126417A1 (es) | Composición farmacéutica de virus no encapsulado | |
| JP7150804B2 (ja) | プラミノーゲンを含む医薬組成物及びその使用 | |
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| HRP20241131T1 (hr) | Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode | |
| BR112022006718A2 (pt) | Composição farmacêutica e métodos de vetor de vírus adeno-associado | |
| JP7223712B2 (ja) | 安定なペプチド組成物 | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| JP2007224052A (ja) | 因子ｉｘ用処方 | |
| BRPI0813948B1 (pt) | Composição líquida farmacêutica de toxina botulínica com estabilidade melhorada | |
| DOP2012000064A (es) | Formulaciones farmaceuticas muy concentradas | |
| CN100546574C (zh) | 注射用扑热息痛液态制剂 | |
| JP2019509311A5 (es) | ||
| MX2018014631A (es) | Formulacion de neurotoxina. | |
| AR122409A1 (es) | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas | |
| AR128785A1 (es) | COMPOSICIONES LIOFILIZADAS QUE COMPRENDEN PARTICULAS DE VIRUS ADENOASOCIADO RECOMBINANTE (rAAV) | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| PE20200847A1 (es) | Composiciones que contienen dulaglutida | |
| US3524916A (en) | Griseofulvin-ethylene glycol monosalicylate compositions | |
| AR131087A1 (es) | Composición farmacéutica de virus sin envoltura | |
| AR131488A1 (es) | Formulaciones de virus adenoasociados | |
| AR110319A1 (es) | Composición para el tratamiento de la osteoartritis | |
| ES2749128T3 (es) | Composición para el tratamiento de rinitis | |
| AR130498A1 (es) | Composiciones farmacéuticas de alta concentración de roflumilast para administración oftálmica | |
| Nathwani | Gene therapy for haemophilia: a very modern success story | |
| BR112017012972B1 (pt) | Composição farmacêutica que compreende plasminogênio e seus usos |